Cargando…
Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
BACKGROUND: Despite an ever-improving understanding of the molecular biology of cancer, the treatment of most cancers has not changed dramatically in the past three decades and drugs that do not discriminate between tumor cells and normal tissues remain the mainstays of anticancer therapy. Since Hsp...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032679/ https://www.ncbi.nlm.nih.gov/pubmed/21235734 http://dx.doi.org/10.1186/1479-5876-9-8 |